Strain of common cold virus could treat cancer cells in bladder

A recent study discovered that a strain of the common cold virus may potentially target, infect and destroy cancer cells in patients with bladder cancer.

Researchers investigated the safety and tolerability of exposure to the oncolytic ('cancer-killing') virus coxsackievirus (CVA21), a naturally occurring strain of the common cold, in fifteen patients with non-muscle invasive bladder cancer (NMIBC).

NMIBC is found in the tissue of the inner surface of the bladder and is the tenth most common cancer in the UK with approximately 10,000 people each year diagnosed with the illness, reported the study published in the journal of Clinical Cancer Research.

Current treatments for this cancer are problematic. Transurethral resection, an invasive procedure that removes all visible lesions, has a high tumor recurrence rate ranging from 50 per cent to 70 per cent as well as a high tumor progression rate between 10 per cent and 20 per cent over a period of two to five years.

Another common course of treatment, immunotherapy with Bacille Calmette-Guerin, a live bacterium used to treat bladder cancer, has been found to have serious side effects in one third of NMIBC patients while one third do not respond to the treatment at all.

During this pioneering study fifteen NMIBC patients, one week prior to pre-scheduled surgery to remove their tumours received CVA21 via a catheter in the bladder. Examination of tissue samples post-surgery discovered that the virus was highly selective, targeting only cancerous cells in the organ and leaving all other cells intact.

The virus was found to have infected cancerous cells and replicated itself causing the cells to rupture and die. Urine samples taken from patients on alternate days detected 'shedding' from the virus indicating that once virally infected cancer cells had died, the newly replicated virus continued to attack more cancerous cells in the organ.

Typically tumors in the bladder do not have immune cells, preventing a patient's own immune system from eliminating cancer as it grows. Evidence suggests treatment with CVA21 inflames the tumor causing immune cells to rush into the cancer environment, targeting and killing the cancer cells.

These tumors devoid of immune cells are known as 'cold' areas immunologically; however, treatment with the virus causes inflammation and immune cell stimulation to create 'immunological 'heat'. 'Hot' tumors in this way are more likely to be rejected by the immune system.

Following treatment with the virus-cell death was identified in the majority of the patients' tumors. In one patient no trace of the cancer was found during surgery.

"Non-muscle invasive bladder cancer is a highly prevalent illness that requires an intrusive and often lengthy treatment plan. Current treatment is ineffective and toxic in a proportion of patients and there is an urgent need for new therapies," said, Hardev Pandha, principal investigator of the study.

"Coxsackievirus could help revolutionise treatment for this type of cancer. Reduction of tumor burden and increased cancer cell death was observed in all patients and removed all trace of the disease in one patient following just one week of treatment, showing its potential effectiveness. Notably, no significant side effects were observed in any patient," he added.

"Traditionally viruses have been associated with illness however in the right situation they can improve our overall health and wellbeing by destroying cancerous cells. Oncolytic viruses such as the coxsackievirus could transform the way we treat cancer and could signal a move away from more established treatments such as chemotherapy," concluded Dr Nicola Annels, one of the researchers of the study.